U.S. Industrial REITs Stock News

Taysha Gene Therapies (TSHA) has reaffirmed FDA alignment on the Biologics License Application pathway for TSHA-102, including pivotal trial design and the potential use of a six month interim analysis for approval. See our latest analysis for Taysha Gene Therapies. The reaffirmed FDA pathway comes after a run in the stock, with a 30 day share price return of 45.95% and a 1 year total shareholder return of 217.62%. This signals strong momentum despite recent earnings losses and ongoing cash...

Liberty Live Holdings, Inc. reported first-quarter 2026 results, with revenue rising to US$63.62 million from US$47.06 million a year earlier, while net loss widened to US$294.14 million from US$29.48 million. This combination of higher sales and a much larger loss highlights how Liberty Live Holdings is balancing growth with the cost of its operations. Next, we’ll examine how the sharp increase in net loss alongside revenue growth shapes Liberty Live Holdings’ broader investment...

Huntsman Corporation recently reported first-quarter 2026 results showing sales of US$1,420 million and a net loss of US$53 million, while shareholders voted against a proposal for an independent board chair and the company affirmed a quarterly dividend of US$0.0875 per share. These developments, alongside ongoing restructuring and European plant-closure programs discussed in earlier filings, highlight the cost and governance pressures shaping Huntsman’s current operating profile. We’ll now...

TowneBank (TOWN) stock drew attention after recent trading left it modestly higher over the past week, but lower over the past month and over the past three months, prompting closer inspection of its fundamentals. See our latest analysis for TowneBank. At a share price of $34.99, TowneBank has a 1-day share price return of 0.46% and a year to date share price return of 5.33%, while its 3 year total shareholder return of 80.75% points to stronger momentum over the longer term. If TowneBank’s...

Host Hotels & Resorts (HST) is in focus after reporting first quarter 2026 results that exceeded profitability expectations, lifted its full year comparable hotel RevPAR guidance, and paired asset sale gains with a special dividend announcement. See our latest analysis for Host Hotels & Resorts. The share price has reacted positively to the first quarter update, with a 1 day share price return of 2.77% and a 7 day share price return of 6.76%. The 1 year total shareholder return of 49.75% and...

ArriVent BioPharma (AVBP) drew fresh attention after announcing FDA clearance of its investigational new drug application for ARR-002, a first-in-class dual-target antibody-drug conjugate for ovarian and endometrial cancers. See our latest analysis for ArriVent BioPharma. Despite a recent dip, with a 1 day share price return down 2.60% and 7 day share price return down 7.20%, ArriVent’s 30 day and year to date share price returns of 14.53% and 38.70%, alongside a 1 year total shareholder...

USA TODAY (TDAY) stock is in focus after the company returned to profitability in the first quarter of 2026, posting positive net income and reaffirming full year earnings guidance despite lower revenue. See our latest analysis for USA TODAY. The earnings return to profit and reaffirmed 2026 guidance have arrived alongside strong momentum, with a 90 day share price return of 26.96% and a 1 year total shareholder return of 105.66%, suggesting sentiment has strengthened around the earnings...

If you are wondering whether Sonos stock still offers value after a strong run or a rough patch, this article breaks down what the current price might be telling you. Over the past year, the stock has returned 44.4%, compared with a 16.1% gain over the last 30 days, while year to date it is down 13.9% and the 5-year return sits at a 55.5% loss. Recent headlines around Sonos have focused on its role in the consumer audio market and how sentiment has shifted around the stock. These stories...

In early May 2026, Caris Life Sciences reported first-quarter revenue of US$216.17 million versus US$120.92 million a year earlier, with net loss improving to US$0.51 million, while also securing MolDX approval for its Caris ChromoSeq whole genome assay and launching the AI-driven Caris MI Clarity breast cancer prognostic test. Together, these developments highlight Caris’ efforts to broaden its precision oncology portfolio across hematologic malignancies and early-stage breast cancer, while...

Arcutis Biotherapeutics (ARQT) is in focus after reporting Q1 2026 revenue of US$105.4 million, a narrowed net loss of US$11.3 million, positive operating cash flow, and reaffirmed full year revenue guidance. See our latest analysis for Arcutis Biotherapeutics. The stock closed at US$20.66 after the results, with a 1-day share price return of -14.52% and a year to date share price return of -28.76%. However, the 1-year total shareholder return is 52.87%, which suggests recent momentum has...

In April 2026, Mirion Technologies reported first-quarter revenue of US$257.6 million, up from US$202.0 million a year earlier, but swung from a small net income to a net loss of US$3.4 million, while also reaffirming its full-year 2026 earnings guidance. A key detail for investors is that Mirion’s full-year revenue growth outlook of approximately 22%–24% includes anticipated benefits from foreign exchange movements and recent acquisitions, which helps explain management’s confidence...

Sana Biotechnology, Inc. recently drew attention with heavy pre-earnings options activity and elevated implied volatility, ahead of its first-quarter earnings release and its past May 12, 2026 presentation at the BofA Securities Healthcare Conference. Investors are closely watching how Sana’s engineered cell therapy pipeline, including its collaborations with Beam Therapeutics and Mayo Clinic, might feature in these updates. We’ll now examine how this heightened options activity ahead of...

In the past quarter, EastGroup Properties reported first quarter 2026 earnings that came in well above prior expectations, prompting analysts to raise their forecasts and highlight stronger near-term growth prospects. This earnings surprise has renewed attention on how the company’s logistics-focused portfolio and development pipeline may support its longer-term investment case. With first quarter earnings outperforming expectations, we’ll now examine how this stronger near-term outlook...

Wondering whether NCR Voyix at US$8.09 is starting to look cheap, or still carries too much risk for the price you pay? The stock has moved sharply in the short term, with a 17.4% return over 7 days and 29.2% over 30 days, although returns are negative at 18.0% year to date and 20.4% over 1 year. These recent moves sit against a longer track record that includes 42.7% and 71.8% returns over 3 and 5 years respectively. These figures may reflect shifting sentiment and changing expectations for...

In early May 2026, Innoviva, Inc. reported first-quarter 2026 results, with revenue of US$97.99 million and net income of US$186.6 million, marking a clear turnaround from the prior year’s loss. Around the same time, Innoviva filed a US$207.99 million shelf registration for up to 9,000,000 common shares tied to its employee stock ownership plan, underscoring management’s focus on employee alignment alongside growth in its recurring royalty and Specialty Therapeutics businesses. We’ll now...

Why Catalyst Pharmaceuticals Stock Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn attention after a period of strong share-price moves, with returns over the past month, past 3 months and year all in positive territory according to recent performance data. For investors tracking US biopharmaceutical stocks focused on rare diseases, this kind of sustained positive return profile can prompt a closer look at how the current share price relates to earnings, profitability and...

Aurinia Pharmaceuticals (AUPH) has drawn fresh attention after reporting first quarter 2026 results. Revenue was US$77.71 million and net income was US$34.36 million, both higher than the prior year period. See our latest analysis for Aurinia Pharmaceuticals. The earnings beat and reiterated 2026 guidance arrived alongside a 4.9% 90 day share price return and an 86.7% 1 year total shareholder return, suggesting strong recent momentum despite short term share price weakness. If Aurinia’s...

Cimpress plc has reported past third-quarter 2026 results showing sales of US$886.21 million versus US$789.47 million a year earlier, with net income of US$13.84 million compared with a net loss of US$8.24 million and basic earnings per share from continuing operations improving from US$0.33 loss to US$0.57. Over the first nine months to March 31, 2026, Cimpress lifted sales to US$2.79 billion and more than doubled net income to US$70.82 million, highlighting materially stronger...

Jacobs Solutions (NYSE:J) has been selected as part of a joint venture to design five new underground stations for Sydney Metro West. The contract covers integrated engineering design services for Australia’s largest transportation project. The win expands Jacobs Solutions’ global transportation infrastructure footprint, with a focus on high-performance, sustainable mass transit. For investors watching the infrastructure and engineering space, this new Sydney Metro West mandate puts Jacobs...

Stepan Company reported past first-quarter 2026 results showing sales of US$604.51 million versus US$593.26 million a year earlier, but it swung from net income of US$19.71 million to a net loss of US$41.41 million, with basic and diluted loss per share from continuing operations of US$1.81 compared with earnings of US$0.86. Despite the move into loss-making territory, Stepan maintained its shareholder payout by affirming a quarterly dividend of US$0.395 per share, payable on June 15, 2026,...

IHS Holding (NYSE:IHS) has completed the divestment of its 51% stake in Brazilian fiber infrastructure venture I-Systems. The stake has been sold to TIM S.A., marking IHS Holding's exit from this Brazilian optical fiber joint venture. IHS Holding, trading at $8.23, has seen its stock return 12.0% year to date and 44.1% over the past year, while its 3 year return stands at 9.2%. This completed I-Systems divestment gives investors a fresh development to consider alongside those share price...

Albemarle (NYSE:ALB) held its annual shareholder meeting on May 5, 2026. Shareholders approved the board slate, executive compensation package, and auditor ratification. A proposal to remove supermajority provisions for certain affiliated transactions narrowly did not pass. Shareholders backed a proposal to make it easier for investors to call special meetings. Albemarle, a major producer in the lithium and specialty chemicals space, sits at the center of debates around corporate governance...

Encompass Health (EHC) stock is in focus after first quarter 2026 results topped Wall Street expectations, management raised full year revenue and adjusted EPS guidance, and the company continued expanding its inpatient rehabilitation hospital network. See our latest analysis for Encompass Health. The recent 1 day share price return of 2.0% to $107.15 and 7 day share price return of 7.2% suggest momentum has picked up following the earnings beat, higher guidance, new hospital opening and...

Wondering if Maximus stock is offering fair value or a potential bargain right now, especially after a tough stretch for returns. The share price last closed at US$66.66, with Maximus delivering a 1.6% return over the past week and 2.3% over the last month, but a 22.9% decline year to date and a 10.6% decline over the last year hint at changing sentiment. Recent coverage has focused on how Maximus fits into investors' long term portfolios and whether the current price reflects its...